Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 31, 2023 16:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Date of Third Quarter 2023 Financial Results Conference Call

ROCKVILLE, MD, Oct. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
September 05, 2023 07:00 ET | Source: MacroGenics, Inc.

MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program

ROCKVILLE, MD, Sept. 05, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
August 31, 2023 16:30 ET | Source: MacroGenics, Inc.

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, Aug. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
August 09, 2023 16:01 ET | Source: MacroGenics, Inc.

MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results

Advancing enrollment of TAMARACK Phase 2 study in metastatic castration-resistant prostate cancer (mCRPC) under revised protocol Initiating lorigerlimab Phase 2 study in mCRPC patients Achieved $50...
July 31, 2023 17:35 ET | Source: MacroGenics, Inc.

MacroGenics Announces Date of Second Quarter 2023 Financial Results Conference Call

ROCKVILLE, MD, July 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
May 09, 2023 16:01 ET | Source: MacroGenics, Inc.

MacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial Results

ZYNYZ™ is third product approved in U.S. that originated from MacroGenics' pipelineMultiple Phase 2 programs advancing in metastatic castration-resistant prostate cancer (mCRPC)Cash runway through...
May 04, 2023 16:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Date of First Quarter 2023 Financial Results Conference Call

ROCKVILLE, MD, May 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
April 24, 2023 18:15 ET | Source: MacroGenics, Inc.

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, April 24, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
March 22, 2023 13:22 ET | Source: MacroGenics, Inc.

MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)

ROCKVILLE, MD, March 22, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
March 15, 2023 16:01 ET | Source: MacroGenics, Inc.

MacroGenics Provides Corporate Update and 2022 Financial Results

Cash runway extended through 2025 with $250 million in non-dilutive funding over past eight months TAMARACK study design modified with objective of accelerating data readoutEncouraging lorigerlimab...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right